

CLAIMS

1. A pharmaceutical composition for use in the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), the composition comprising nemolizumab or an equivalent thereof, in which the subject does not have atopic dermatitis.
- 5 2. A pharmaceutical composition according to Claim 1, in which the subject has prurigo nodularis (PN).
3. A pharmaceutical composition according to Claim 2, in which the subject has been diagnosed of PN for at least 6 months.
4. A pharmaceutical composition according to Claim 1, 2 or 3, in which the subject has at
10 least 20 nodules on his/her body with a bilateral distribution.
5. A pharmaceutical composition according to any preceding claim, in which the subject has prurigo lesions on upper limbs.
6. A pharmaceutical composition according to any preceding claim, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
- 15 7. A pharmaceutical composition according to any preceding claim, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).
8. A pharmaceutical composition according to any preceding claim, further comprising a carrier.
9. A pharmaceutical composition according to Claim 8, in which the carrier is a
20 pharmaceutically acceptable carrier.
10. A pharmaceutical composition according to any preceding claim, in which the nemolizumab or equivalent thereof is to be administered according to a flat dosing regimen.
11. A pharmaceutical composition according to any of Claims 1 to 9, in which the nemolizumab or equivalent thereof is to be administered according to a loading dose regimen.
- 25 12. A pharmaceutical composition according to any preceding claim, in which the composition comprises 0.01 mg/kg to 0.1 mg/kg, 0.1 mg/kg to 0.5 mg/kg, 0.5 mg/kg to 1.5

mg/kg, 1.5 mg/kg to 2.5 mg/kg, or 2.5 mg/kg to 10 mg/kg of nemolizumab or the equivalent thereof.

13. A pharmaceutical composition according to any of Claims 1 to 11, in which the composition comprises 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55
5 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg of nemolizumab or the equivalent thereof.

14. Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), in which the subject does not have atopic dermatitis.

10 15. Use according to Claim 14, in which the subject has prurigo nodularis (PN).

16. Use according to Claim 15, in which the subject has been diagnosed of PN for at least 6 months.

17. Use according to any of Claims 14 to 16, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.

15 18. Use according to any of Claims 14 to 17, in which the subject has prurigo lesions on upper limbs.

19. Use according to any of Claims 14 to 18, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).

20 20. Use according to any of Claims 14 to 19, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).

21. Use according to any of Claims 14 to 20, in which the nemolizumab or equivalent thereof is to be administered according to a flat dosing regimen.

22. Use according to any of Claims 14 to 20, in which the nemolizumab or equivalent thereof is to be administered according to a loading dose regimen.

25 23. Use according to any of Claims 14 to 22, in which the nemolizumab or the equivalent thereof is to be administered at a dose of 0.01 mg/kg to 0.1 mg/kg, 0.1 mg/kg to 0.5 mg/kg, 0.5 mg/kg to 1.5 mg/kg, 1.5 mg/kg to 2.5 mg/kg, or 2.5 mg/kg to 10 mg/kg.

24. Use according to any of Claims 14 to 22, in which the nemolizumab or the equivalent thereof is to be administered at a dose of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg.
25. Use according to any of Claims 14 to 24, in which the nemolizumab or the equivalent thereof is to be administered by a topical or parenteral route.
26. Use according to any of Claims 14 to 25, in which the nemolizumab or the equivalent thereof is to be administered subcutaneously.
27. Use according to any of Claims 14 to 26, in which the nemolizumab or the equivalent thereof is to be administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
28. A pharmaceutical composition for use in the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), the composition comprising within the range of 30 mg to 60 mg of nemolizumab or an equivalent thereof.
29. A pharmaceutical composition according to Claim 28, in which the subject has prurigo nodularis (PN).
30. A pharmaceutical composition according to Claim 29, in which the subject has been diagnosed of PN for at least 6 months.
31. A pharmaceutical composition according to any of Claims 28 to 30, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.
32. A pharmaceutical composition according to any of Claims 28 to 31, in which the subject has prurigo lesions on upper limbs.
33. A pharmaceutical composition according to any of Claims 28 to 32, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
34. A pharmaceutical composition according to any of Claims 28 to 33, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).
35. A pharmaceutical composition according to any of Claims 28 to 34, in which the subject does not have atopic dermatitis.

36. A pharmaceutical composition according to any of Claims 28 to 35, further comprising a pharmaceutically acceptable carrier.

37. A pharmaceutical composition according to any of Claims 28 to 36, which is characterized in that the pharmaceutical composition is used such that the nemolizumab or equivalent thereof is to be administered to a subject according to a flat dosing regimen.

38. A pharmaceutical composition according to any of Claims 28 to 36, which is characterized in that the pharmaceutical composition is used such that the nemolizumab or equivalent thereof is to be administered to a subject according to a loading dose regimen.

39. A pharmaceutical composition according to any of Claims 28 to 38, which is characterized in that the pharmaceutical composition is used such that the pharmaceutical composition is to be administered to a subject once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

40. A pharmaceutical composition according to any of Claims 28 to 39, in which the pharmaceutical composition comprises nemolizumab.

41. A pharmaceutical composition according to any of Claims 28 to 40, in which the pharmaceutical composition comprises 30 mg or 60 mg of nemolizumab.

42. A pharmaceutical composition according to Claim 41, which is characterized in that the pharmaceutical composition is used such that the pharmaceutical composition is to be administered to a subject once every four weeks.

43. Use of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), in which the medicament comprises within the range of 30 mg to 60 mg of nemolizumab or an equivalent thereof.

44. Use according to Claim 43, in which the subject has prurigo nodularis (PN).

45. Use according to Claim 44, in which the subject has been diagnosed of PN for at least 6 months.

46. Use according to Claim 43, 44 or 45, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.

47. Use according to any of Claims 43 to 46, in which the subject has prurigo lesions on upper limbs.

5 48. Use according to any of Claims 43 to 47, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).

49. Use according to any of Claims 43 to 48, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).

10 50. Use according to any of Claims 43 to 49, in which the subject does not have atopic dermatitis.

51. Use according to any of Claims 43 to 50, which is characterized in that the medicament is used such that the nemolizumab or equivalent thereof is to be administered to a subject according to a flat dosing regimen.

15 52. Use according to any of Claims 43 to 50, which is characterized in that the medicament is used such that the nemolizumab or equivalent thereof is to be administered to a subject according to a loading dose regimen.

20 53. Use according to any of Claims 43 to 52, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

54. Use according to any of Claims 43 to 53, in which the medicament comprises nemolizumab.

25 55. Use according to any of Claims 43 to 54, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject at a dose of 30 mg or 60 mg.

56. Use according to Claim 55, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once every four weeks.

CLAIMS

1. Use of nemolizumab in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), in which the subject does not have atopic dermatitis.
- 5 2. Use according to Claim 1, in which the subject has prurigo nodularis (PN).
3. Use according to Claim 2, in which the subject has been diagnosed of PN for at least 6 months.
4. Use according to Claim 1, 2 or 3, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.
- 10 5. Use according to any preceding claim, in which the subject has prurigo lesions on upper limbs.
6. Use according to any preceding claim, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
7. Use according to any preceding claim, in which the pruritus has been assigned a score of
15 at least 7 on the Numerical Rating Scale (NRS).
8. Use according to any preceding claim, in which the nemolizumab is to be administered according to a flat dosing regimen.
9. Use according to any of Claims 1 to 7, in which the nemolizumab is to be administered according to a loading dose regimen.
- 20 10. Use according to any of Claims 1 to 8, in which the nemolizumab is to be administered at a dose of 0.01 mg/kg to 0.1 mg/kg, 0.1 mg/kg to 0.5 mg/kg, 0.5 mg/kg to 1.5 mg/kg, 1.5 mg/kg to 2.5 mg/kg, or 2.5 mg/kg to 10 mg/kg.
11. Use according to any of Claims 1 to 8, in which the is to be administered at a dose of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg,
25 75 mg, 80 mg, 85 mg, 90 mg.
12. Use according to any preceding claim, in which the nemolizumab is to be administered by a topical or parenteral route.

13. Use according to any of Claims 1 to 11, in which the nemolizumab is to be administered subcutaneously.
14. Use according to any preceding claim, in which the nemolizumab is to be administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
15. Use of nemolizumab in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having chronic prurigo (CP), in which the medicament comprises within the range of 30 mg to 60 mg of nemolizumab.
16. Use according to Claim 15, in which the subject has prurigo nodularis (PN).
17. Use according to Claim 16, in which the subject has been diagnosed of PN for at least 6 months.
18. Use according to Claim 15, 16 or 17, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.
19. Use according to any of Claims 15 to 18, in which the subject has prurigo lesions on upper limbs.
20. Use according to any of Claims 15 to 19, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
21. Use according to any of Claims 15 to 20, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).
22. Use according to any of Claims 15 to 21, in which the subject does not have atopic dermatitis.
23. Use according to any of Claims 15 to 22, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject according to a flat dosing regimen.
24. Use according to any of Claims 15 to 22, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject according to a loading dose regimen.

25. Use according to any of Claims 15 to 24, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
- 5 26. Use according to any of Claims 15 to 25, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject at a dose of 30 mg or 60 mg.
27. Use according to Claim 26, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once every four weeks.